Detalhe da pesquisa
1.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
J Neurol Neurosurg Psychiatry
; 95(5): 392-400, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37963723
2.
Clinical scales in progressive MS: predicting long-term disability.
Mult Scler
; 18(3): 345-50, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21868487
3.
Outcome measurement in multiple sclerosis: detection of clinically relevant improvement.
Mult Scler
; 16(5): 604-10, 2010 May.
Artigo
Inglês
| MEDLINE | ID: mdl-20086019
4.
The size of the treatment effect: do patients and proxies agree?
BMC Neurol
; 9: 12, 2009 Mar 25.
Artigo
Inglês
| MEDLINE | ID: mdl-19317921
5.
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.
BMC Neurol
; 8: 2, 2008 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-18307788